Core Insights - Qilu Pharmaceutical's innovative drug, Irukak (伊鲁阿克片), for ALK-positive non-small cell lung cancer (NSCLC) was launched on JD Health, enhancing the product matrix for lung cancer precision treatment [1][3] - JD Health aims to leverage its position as the "first station for new specialty drug launches" to improve drug accessibility and treatment standardization for patients [1][4] Group 1: Drug and Market Overview - Lung cancer is the most prevalent and deadly malignancy in China, with NSCLC accounting for over 80% of cases [3] - ALK gene fusion mutations occur in approximately 3%-7% of NSCLC cases, predominantly in younger individuals, women, and non-smokers, and are known for their high response rates to targeted therapies [3] - Irukak, as a next-generation ALK inhibitor, demonstrates strong inhibition of ALK kinase activity, good coverage of common resistance mutations, and excellent blood-brain barrier penetration [3][4] Group 2: Clinical Efficacy - Clinical studies show that Irukak has a remarkable intracranial objective response rate (ORR) of 85.7%, providing significant treatment assurance for ALK-positive patients prone to brain metastases [3][4] - Long-term survival data for Irukak indicates promising potential for extending patient survival [4] Group 3: JD Health's Strategic Positioning - JD Health has previously introduced several ALK-targeted drugs, including Crizotinib, Alectinib, and Brigatinib, enhancing its service capabilities in oncology [4] - The launch of Irukak on JD Health not only offers more personalized treatment options but also strengthens the company's ability to supply and service major disease medications [4] - JD Health plans to continue collaborating with leading domestic and international pharmaceutical companies to promote innovative treatment solutions and improve healthcare accessibility [4]